Cormorant Asset Management’s Cellectar Biosciences, Inc. CLRBW Stock Holding History

Cormorant Asset Management’s Portfolio CLRBW Stock Details CLRBW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-52,999	Closed	-$3K	–	78
2019 Q2	$3K	Hold	52,999	–	–	﹤0.01%	72
2019 Q1	$5K	Hold	52,999	–	–	﹤0.01%	64
2018 Q4	$3K	Hold	52,999	–	–	﹤0.01%	70
2018 Q3	$4K	Hold	52,999	–	–	﹤0.01%	65
2018 Q2	$10K	Hold	52,999	–	–	﹤0.01%	58
2018 Q1	$6K	Hold	52,999	–	–	﹤0.01%	52
2017 Q4	$5K	Hold	52,999	–	–	﹤0.01%	52
2017 Q3	$8K	Hold	52,999	–	–	﹤0.01%	51
2017 Q2	$12K	Hold	52,999	–	–	﹤0.01%	71
2017 Q1	$20K	Hold	52,999	–	–	﹤0.01%	75
2016 Q4	$10K	Hold	52,999	–	–	﹤0.01%	77
2016 Q3	$13K	Hold	52,999	–	–	﹤0.01%	84
2016 Q2	$29K	Buy	+52,999	New	+$32.3K	﹤0.01%	84

Cormorant Asset Management's CLRBW Position: Q3 2019 in Review

Cormorant Asset Management sold out of Cellectar Biosciences, Inc. (CLRBW) in Q3 2019, closing a stake of 52,999 shares — an estimated $3K sold.

Cormorant Asset Management first reported a position in CLRBW in Q2 2016 and held it in 13 quarters. The position peaked at $29K in Q2 2016. 0 funds tracked by Wall St. Rank hold CLRBW as of Q3 2019.

Cormorant Asset Management reported no remaining Cellectar Biosciences, Inc. position as of Q3 2019 after selling out during the quarter.
Cormorant Asset Management sold 52,999 Cellectar Biosciences, Inc. shares in Q3 2019, an estimated $3K.
Cormorant Asset Management first reported a position in Cellectar Biosciences, Inc. in Q2 2016 and held it in 13 quarters.
Cormorant Asset Management's Cellectar Biosciences, Inc. position peaked at $29K in Q2 2016.
0 funds tracked by Wall St. Rank held Cellectar Biosciences, Inc. as of Q3 2019.

Based on Cormorant Asset Management's 13F filing for Q3 2019, filed 14 Nov 2019.